4ZAU

AZD9291 complex with wild type EGFR


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.196 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

Yosaatmadja, Y.Silva, S.Dickson, J.M.Patterson, A.V.Smaill, J.B.Flanagan, J.U.McKeage, M.J.Squire, C.J.

(2015) J Struct Biol 192: 539-544

  • DOI: 10.1016/j.jsb.2015.10.018
  • Primary Citation of Related Structures:  
    4ZAU

  • PubMed Abstract: 
  • The discovery of genetic drivers of lung cancer in patient sub-groups has led to their use as predictive biomarkers and as targets for selective drug therapy. Some of the most important lung cancer drivers are mutations in the EGFR gene, for example, the exon 19 deletions and the L858R variant that confer sensitivity to the front line drugs erlotinib and gefitinib; the acquired T790M variants confer drug resistance and a poor prognosis ...

    The discovery of genetic drivers of lung cancer in patient sub-groups has led to their use as predictive biomarkers and as targets for selective drug therapy. Some of the most important lung cancer drivers are mutations in the EGFR gene, for example, the exon 19 deletions and the L858R variant that confer sensitivity to the front line drugs erlotinib and gefitinib; the acquired T790M variants confer drug resistance and a poor prognosis. A challenge then in targeting EGFR is to produce drugs that inhibit both sensitising variants and resistance variants, leaving wild type protein in healthy cells unaffected. One such agent is AstraZeneca's "breakthrough" AZD9291 molecule that shows a 200-fold selectivity for T790M/L858R over wild type EGFR. Our X-ray crystal structure reveals the binding mode of AZD9291 to the kinase domain of wild type EGFR.


    Organizational Affiliation

    School of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, c/o The University of Auckland, Private Bag 92019, Auckland, New Zealand. Electronic address: c.squire@auckland.ac.nz.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Epidermal growth factor receptorA330Homo sapiensMutation(s): 0 
Gene Names: EGFRERBBERBB1HER1
EC: 2.7.10.1
Find proteins for P00533 (Homo sapiens)
Explore P00533 
Go to UniProtKB:  P00533
NIH Common Fund Data Resources
PHAROS:  P00533
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
YY3
Query on YY3

Download Ideal Coordinates CCD File 
B [auth A]N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
C28 H33 N7 O2
DUYJMQONPNNFPI-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
YY3IC50:  23   nM  BindingDB
YY3IC50:  300   nM  BindingDB
YY3IC50:  17   nM  BindingDB
YY3IC50:  270   nM  BindingDB
YY3IC50:  1   nM  BindingDB
YY3IC50:  260   nM  BindingDB
YY3IC50:  1.2000000476837158   nM  BindingDB
YY3IC50:  15   nM  BindingDB
YY3IC50:  0.5   nM  BindingDB
YY3IC50:  14   nM  BindingDB
YY3IC50:  225   nM  BindingDB
YY3IC50:  2   nM  BindingDB
YY3IC50:  13   nM  BindingDB
YY3Ki:  3.5   nM  BindingDB
YY3IC50:  1.7999999523162842   nM  BindingDB
YY3IC50:  12   nM  BindingDB
YY3IC50:  100   nM  BindingDB
YY3IC50:  41   nM  BindingDB
YY3IC50:  36   nM  BindingDB
YY3IC50:  2   nM  BindingDB
YY3EC50:  43   nM  BindingDB
YY3EC50:  667   nM  BindingDB
YY3IC50:  494   nM  BindingDB
YY3IC50:  2.4000000953674316   nM  BindingDB
YY3IC50:  480   nM  BindingDB
YY3IC50:  409   nM  BindingDB
YY3IC50:  0.8999999761581421   nM  BindingDB
YY3IC50:  4.599999904632568   nM  BindingDB
YY3IC50:  3.4000000953674316   nM  BindingDB
YY3IC50:  74   nM  BindingDB
YY3IC50:  77   nM  BindingDB
YY3IC50:  56   nM  BindingDB
YY3Ki:  14   nM  BindingDB
YY3IC50:  100   nM  BindingDB
YY3IC50:  3   nM  BindingDB
YY3IC50:  750   nM  BindingDB
YY3IC50:  11   nM  BindingDB
YY3Ki:  3.200000047683716   nM  BindingDB
YY3IC50:  150   nM  BindingDB
YY3IC50:  141   nM  BindingDB
YY3IC50:  120   nM  BindingDB
YY3Ki:  2.200000047683716   nM  BindingDB
YY3IC50:  1   nM  BindingDB
YY3IC50:  1.399999976158142   nM  BindingDB
YY3IC50:  1.600000023841858   nM  BindingDB
YY3IC50:  3.0999999046325684   nM  BindingDB
YY3IC50:  109   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.196 
  • Space Group: I 2 3
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 144.886α = 90
b = 144.886β = 90
c = 144.886γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2015-11-11
    Type: Initial release
  • Version 1.1: 2015-11-18
    Changes: Database references
  • Version 1.2: 2015-12-02
    Changes: Database references
  • Version 1.3: 2020-09-09
    Changes: Database references, Derived calculations, Structure summary